These are compounds, either pharmaceutical or derived from natural sources, employed clinically to inhibit or slow the process of glycation, which is the non-enzymatic bonding of sugars to proteins or lipids. Glycation results in the formation of Advanced Glycation End products (AGEs), known contributors to age-related tissue stiffness and chronic disease pathology. Utilizing these agents is a preventative measure to preserve structural integrity and cellular function.
Origin
The term arises directly from the biochemical understanding of the glycation reaction, a key pathway in diabetes complications and the general aging process. Clinical interest in anti-glycation agents grew as researchers established the link between accumulated AGEs and the degradation of long-lived proteins such as collagen and elastin. This therapeutic area bridges metabolic health with dermatological and cardiovascular longevity.
Mechanism
Anti-glycation agents function through several pathways, including sequestering reactive dicarbonyl compounds like methylglyoxal before they can react with amino groups on proteins. Some agents act as carbonyl scavengers, effectively detoxifying the cellular environment of these damaging intermediates. By inhibiting the formation and accumulation of AGEs, these compounds help maintain the functional elasticity of vascular walls and dermal matrix proteins.
We use cookies to personalize content and marketing, and to analyze our traffic. This helps us maintain the quality of our free resources. manage your preferences below.
Detailed Cookie Preferences
This helps support our free resources through personalized marketing efforts and promotions.
Analytics cookies help us understand how visitors interact with our website, improving user experience and website performance.
Personalization cookies enable us to customize the content and features of our site based on your interactions, offering a more tailored experience.